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S U M M A R Y
Objectives: The objectives of this study were to evaluate the interactions between linezolid (LZD) and
second-line anti-tuberculosis (TB) agents in susceptible and multidrug-resistant (MDR) TB in vitro, and
to validate the in vitro results in a murine TB model.
Methods: The minimum inhibitory concentrations of LZD and seven second-line anti-TB drugs against
H37Rv and three multidrug-resistant clinical isolates were determined by Alamar Blue assay, and the
interaction patterns of LZD and the seven second-line anti-TB agents against the four isolates were
studied using a dynamic checkerboard method. The activities of these combinations against
Mycobacterium tuberculosis were evaluated in a murine model of TB.
Results: The combination of LZD + capreomycin exhibited partial synergism for three of four isolates, LZD
+ para-aminosalicylic acid exhibited partial synergism for two of four isolates, and LZD + levoﬂoxacin and
LZD + amikacin exhibited partial synergism for one of four isolates; all other combinations showed
indifference or an additive effect in vitro. The activities of six combinations and the standard regimen
rifampicin + isoniazid + pyrazinamide were investigated in a murine model of TB (infection with H37Rv).
Signiﬁcant reductions in colony-forming units (CFU) were found in LZD + capreomycin and LZD +
clofazimine groups when the CFU in the lungs on day 0 (the day of beginning treatment) was compared
with the CFU in the lungs after 2 months of treatment.
Conclusions: These combinations of LZD and second-line anti-TB drugs were all active against MDR-TB
with indifference or an additive effect, except LZD + capreomycin, which showed partial synergy.
 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Although the World Health Organization (WHO) has spared no
effort in reducing the number of tuberculosis (TB) cases, the
prospect of controlling TB is still not optimistic.1,2 With the
emergence of multidrug-resistant tuberculosis (MDR-TB, i.e. TB
that is resistant to at least isoniazid (INH) and rifampicin (RIF)) and
extensively drug-resistant tuberculosis (XDR-TB, i.e. TB that is
resistant to INH, RIF, any ﬂuoroquinolone, and at least one of three
injectable second-line drugs), the control of the disease is* Corresponding author.
E-mail address: guozhenyong0425@sina.com (Z. Guo).
http://dx.doi.org/10.1016/j.ijid.2016.08.027
1201-9712/ 2016 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).increasingly compromised. To treat MDR-TB and XDR-TB, four
or ﬁve second-line anti-TB drugs are often chosen as part of the
treatment regimen. The WHO has recommended the basic
principle of formulating regimens that consist of one injectable
drug and one ﬂuoroquinolone as part of a combination that is
generally made up of four or ﬁve agents, along with another
second-line anti-TB agent if the Mycobacterium tuberculosis strain
is found to be resistant to ﬂuoroquinolone. However, these
regimens are less active,3 and the treatment duration is prolonged
(WHO, 2006),4 leaving the need for new drugs and combinations
against MDR- and XDR-TB.5
Linezolid (LZD) has been reported to exhibit powerful anti-TB
activity, with a minimum inhibitory concentration (MIC) range of
0.06 to 1 mg/ml and a MIC90 (MIC required to inhibit the growth ofciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
W. Zhao et al. / International Journal of Infectious Diseases 52 (2016) 23–282490% of organisms) of 0.5 mg/ml in vitro.6 LZD was able to clear the
organisms in the lungs of mice when combined with other second-
line anti-TB drugs.7 In patients, regimens containing LZD displayed
favorable effects against MDR-TB, with successful treatment in
67.99% of patients.8 Similar results were found against XDR-TB.9
Several other second-line anti-TB drugs are often included in
the combinations containing LZD that are used against MDR-TB
and XDR-TB. However because of the different mechanisms of
these agents, the interactions between LZD and other anti-TB drugs
are in some cases beneﬁcial and in other cases harmful to the
activities of the regimens against M. tuberculosis. For example,
antagonism has been found between INH, pyrazinamide (PZA), and
LZD, because LZD can reduce the absorption of INH and PZA.
Therefore, LZD should not be administered with INH or PZA at the
same time.10 These results suggest that it is important to study the
interactions between LZD and second-line anti-TB drugs. In this
study, these interactions were evaluated in sensitive and MDR M.
tuberculosis in vitro and sensitive M. tuberculosis in vivo.
2. Materials and methods
2.1. Bacterial strains and culture conditions
M. tuberculosis H37Rv (ATCC 27294) and three clinical MDR
isolates of M. tuberculosis known to be resistant to RIF and INH
(12179, 7153, and 5116; donated by the National Conference
Laboratory, China) were used in this study. The organisms were
grown at 37 8C with 5% ambient CO2 for 14 days in Middlebrook
7H9 broth (Becton Dickinson, Sparks, MD, USA) supplemented
with 0.2% (vol/vol) glycerol (Sigma, St. Louis, MO, USA), 10% (vol/
vol) oleic acid–albumin–dextrose–catalase (OADC; Becton Dick-
inson), and 0.05% (vol/vol) Tween 80 (Sigma, St. Louis, MO, USA).
Bacteria were washed and suspended in phosphate buffered saline
(PBS) and passed through an 8-mm pore-size ﬁlter to eliminate
clumps. The ﬁltrates were aliquoted, stored at 80 8C, and used
within 30 days.
2.2. Drugs and chemicals
The compounds used were purchased from various manufac-
turers. Levoﬂoxacin (LFX) was from Shuanghe Pharmaceutical Co.,
Ltd (Beijing, China); clofazimine (CFZ) was from Nanjing Liye
Pharmaceutical Co., Ltd (Nanjing, Jiangsu, China); amikacin (AM),
para-aminosalicylic acid (PAS), kanamycin (KM), prothionamide
(PT), and capreomycin (CPM) were from Shanghai Xinyi Pharma-
ceutical Co., Ltd (Shanghai, China); RIF, PZA, and INH were from
Sigma (St. Louis, MO, USA); moxiﬂoxacin (MFX) was from Bayer;
LZD was from Pﬁzer.
2.3. Determination of the MIC and synergy
Initial stock solutions of INH, RIF, ethambutol (EMB), LFX, MFX,
CPM, AM, PAS, CFZ, and AM were made in dimethylsulfoxide
(DMSO) at 10 or 20 g/l, from which further dilutions were made in
7H9 broth. To avoid interference by the solvent, the highest
concentration of DMSO was 0.5%. Individual MICs of antimicrobial
agents were determined for each isolate by microplate Alamar Blue
assay (MABA).11 Brieﬂy, serial two-fold concentrations of drugs
were used to determine the MICs of these agents against the four
isolates. The MICs of combinations of LZD with other second-line
anti-TB agents were determined by dynamic checkerboard method
in 96-well microtiter plates. Each well contained LZD and one
second-line drug at two-fold dilutions dispensed in a checkerboard
fashion.12 The ﬁnal concentrations of both drugs ranged from 1/8
to 1 times the MIC for each.The interpretation of the data was achieved by calculating the
fractional inhibitory concentration (FIC) as follows: FIC = (A/MICA)
+ (B/MICB), where A and B represent the MICs of each combination,
while MICA and MICB are the MICs of each drug alone. The FIC was
interpreted as follows: synergy (FIC index 0.5) was deﬁned as a
four-fold or greater decrease in MIC of both drugs in combination
compared with the drugs tested individually. Partial synergy was
deﬁned as a four-fold or greater decrease in MIC of one agent and a
two-fold decrease in MIC of the other agent (FIC >0.5, but<1). An
additive effect was deﬁned as a two-fold drop in MIC with both
agents (FIC = 1). Indifference was noted when there was no change
in MIC whether the agents were tested alone or in combination (FIC
>1, but <4) and the results were interpreted as antagonistic when
there was a four-fold increase in MIC for both agents when the
drugs were tested in combination compared with the results when
each drug was tested alone (FIC 4).13
2.4. Aerosol infection
Male 6-week-old BALB/c mice were purchased from Beijing
Vital River Laboratory Animal Technology Co., Ltd (Beijing, China)
and were infected with H37Rv using a Glas-col inhalation exposure
system (Glas-col Inc., Terre Haute, IN, USA) and a fresh log-phase
broth culture with the goal of implanting approximately 3.53 log10
CFU in the lungs of each mouse. Five mice were sacriﬁced
the following day to determine the amount of CFU implanted in the
lungs. All animal procedures were approved by the Animal Care
and Use Committee of Beijing Tuberculosis and Thoracic Tumor
Institution.
2.5. Chemotherapy
After infection, the mice were randomized into 15 groups. The
ﬁrst group was a negative control group in which the mice were
infected but untreated. The last group was a positive control group
in which the mice were treated with the standard regimen of RIF +
INH + PZA. Mice in the remaining groups were treated with second-
line anti-TB drugs alone or in combination with LZD. Treatment
began 15 days later (day 0) to achieve a larger bacterial population
and was administered 5 days per week. For consistency, 4 weeks of
treatment was considered as corresponding to 1 month. The drugs
were administered at the following dosages (in mg/kg/day): LZD
100, LFX 200, PAS 750, PT 100, CFZ 20, AM 150, CPM 150, PZA 150,
RIF 20, and INH 25. These dosages are similar to those used in
previous experiments by this study group,7 and in other studies.14
AM and CPM were diluted in normal saline. The remaining drugs
were suspended at the desired concentrations in distilled water
containing 0.05% agar. Drug suspensions were prepared weekly
and stored at 4 8C. All regimens were administered for 2 months.
AM and CPM were given by subcutaneous injection 5 days per
week. The remaining drugs were administered by gavage.
2.6. Assessment of infection and treatment
For baseline values, ﬁve infected and ﬁve untreated mice were
decapitated on days 1 and 15 after infection, respectively (day 14
and day 0 in relation to the initiation of treatment). Five mice per
group were sacriﬁced after 1 and 2 months of treatment for the
determination of lung CFU counts. The severity of infection and the
effectiveness of the treatments were assessed by spleen weight
and the number of CFU in the lungs. On days 14 and 0 and after
1 month of treatment, the number of CFU in the lungs was
determined by plating four serial 10-fold dilutions of homogenized
suspensions onto OADC-enriched 7H11 agar medium. After
2 months of therapy, the entire suspension prepared from each
individual organ, which was supposed to contain few bacilli, was
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The results from the cultures were recorded after incubation at
37 8C for 4 weeks. The bactericidal effect of the treatment was
deﬁned as a signiﬁcant decrease in the mean number of CFU in the
treated group compared with the pre-treatment value. To prevent
the carry-over effect of CFZ, 0.4% activated charcoal was added to
the OADC-enriched 7H11 agar medium when the lung CFU counts
of those groups treated with CFZ or LZD + CFZ were determined.
2.7. Statistical analysis
CFU counts were log10-transformed before analysis and
expressed as the CFU log10  standard error. The experimental
group means were compared to the untreated group by one-way
analysis of variance with Dunnett’s post-test for multiple compar-
isons. Differences were considered signiﬁcant at the 95% conﬁdence
level. The data analysis was performed using SPSS version 17.0 soft-
ware (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Determination of MICs
MICs of RIF, INH, PT, MFX, LFX, PAS, KM, CPM, AM, and CFZ were
determined according to a standard two-fold agar dilution
method under the deﬁned conditions described above. For
H37Rv, these drugs were all sensitive and exhibited MIC values
ranging between 0.05 mg/l and 2 mg/l, similar to previous results.
For the other three clinical isolates, high resistance to RIF, INH, and
PT was observed. However, all of these three isolates were still
susceptible to MFX, LFX, PAS, KM, CPM, AM, and CFZ with MICs
ranging between 0.125 mg/l and 8 mg/l. Among these second-line
drugs, MFX had the greatest bactericidal activity in vitro against
the isolates investigated in the present study, with a MIC of
0.125 mg/l, while PT had the lowest activity against the three
resistant clinical isolates (MIC >32 mg/l), which were all resistant
to INH (Table 1).Table 2
Combination minimum inhibitory concentrations (MICs; mg/l) of antimicrobial agents
isolates of M. tuberculosis, and the combined fractional inhibitory concentrationsa
Combined drugs Combination MICs 
H37Rv 12179 7153 
LZD + MFX 0.25/0.062 0.125/0.062 0.25/0.062 
LZD + LFX 0.25/0.25 0.062/0.25 0.25/0.25 
LZD + PAS 0.25/0.031 0.125/0.062 0.5/0.125 
LZD + KM 0.25/0.5 0.25/0.5 0.25/1 
LZD + CPM 0.25/0.5 0.125/0.5 0.25/4 
LZD + AM 0.5/0.125 0.125/0.25 0.25/1 
LZD + CFZ 0.25/0.06 0.25/0.125 0.5/0.96 
LZD, linezolid; MFX, moxiﬂoxacin; LFX, levoﬂoxacin; PAS, para-aminosalicylic acid; KM
a Fractional inhibitory concentration: an FIC index 0.5 indicates a synergistic ef
FIC = 1 indicates indifference; an FIC >1 but <4 indicates antagonism.
Table 1
Minimum inhibitory concentrations (MICs; mg/l) of antimicrobial agents against Myco
tuberculosis in vitro
Strain RIF INH PT LZD MFX 
H37Rv 0.1 0.05 2 0.5 0.125 
12179 >40 >40 >64 0.25 0.125 
7153 10 >40 >32 0.5 0.125 
5116 >40 >40 >32 1 0.125 
RIF, rifampicin; INH, isoniazid; PT, prothionamide; LZD, linezolid; MFX, moxiﬂoxacin; LF
AM, amikacin; CFZ, clofazimine.3.2. Determination of the synergistic activity in vitro
The MICs of combinations of LZD and MFX, LFX, PAS, KM, CPM,
AM, and CFZ against H37Rv and the three MDR M. tuberculosis
isolates are listed in Table 2.
Antagonistic activity was not observed for any of these
combinations. In most cases, sub-inhibitory concentrations of
LZD enhanced the anti-TB activity of MFX, LFX, PAS, KM, CPM, AM,
and CFZ. Among the combinations, LZD + CPM displayed partial
synergistic activity for three of the four isolates, as demonstrated
by the combined FIC of 0.75. The MICs of CPM against these three
isolates (individual MIC 2 mg/l for all) was reduced to one-fourth
(0.5 mg/l) when CPM was used in combination with concentra-
tions of LZD equal to 1/2  MIC (0.25 mg/l). The combination of LZD
+ PAS displayed partial synergistic activity for two of the four
isolates, while the combination of LZD + LFX displayed partial
synergistic activity for 12179 and the combination of LZD + CFZ
displayed partial synergistic activity for H37Rv (FIC = 0.75). Other
combinations showed additive effects or indifference. Due to the
high resistance of clinical isolates to PT (>32 mg/l), the interaction
effect of PT and LZD was not determined.
3.3. Mean spleen weight
The mean spleen weight on day 0 was 0.0903  0.1085 g. For
mice receiving individual drugs (except LFX and PAS) or combination
therapy, the spleen weights after 1 or 2 months of treatment were
signiﬁcantly lower than those of the untreated group (p < 0.05) and
the spleen weights remained lower throughout the experiment
(Table 3). There were no differences in spleen weights among the
mice treated with LZD, PT, AM, CPM, and CFZ alone or in combination
throughout the experiment.
PAS alone failed to decrease the spleen weight after 1 or
2 months of treatment. LFX alone also did not reduce the spleen
weight after 1 month of treatment, but did signiﬁcantly reduce the
spleen weight after 2 months of treatment when compared with
the control group (p = 0.019). When combined with LZD, PAS against Mycobacterium tuberculosis H37Rv and three multidrug-resistant clinical
Combined FIC
5116 H37Rv 12179 7153 5116
1/0.062 1 1 1 1.5
0.5/0.25 1 0.75 1 1
0.25/0.5 0.75 1 1.125 0.75
0.5/2 1.125 1.125 0.75 1
0.5/0.5 0.75 0.75 1 0.75
0.5/0.5 1.125 1 1 0.75
0.5/0.24 0.75 1.125 1.125 1
, kanamycin; CPM, capreomycin; AM, amikacin; CFZ, clofazimine.
fect between the two drugs; an FIC >0.5 but <1 indicates partial synergy; an
bacterium tuberculosis H37Rv and three multidrug-resistant clinical isolates of M.
LFX PAS KM CPM AM CFZ
0.5 0.125 2 2 1 0.24
0.5 0.125 2 2 0.5 0.48
0.5 1 4 8 2 3.84
0.5 1 4 2 2 0.48
X, levoﬂoxacin; PAS, para-aminosalicylic acid; KM, kanamycin; CPM, capreomycin;
Table 3
Spleen weights of mice sacriﬁced after 1 month (M1) and 2 months (M2) of treatment
Treatment groups Mean spleen weight (g)
M1 p-Valuea M2 p-Valuea
Control 0.1818  0.0324 - 0.2428  0.0429 -
LZDb 0.0985  0.0153 0.000 0.1041  0.0088 0.000
LFX 0.1773  0.0339 1.000 0.1936  0.0466 0.019
PAS 0.161  0.0312 0.618 0.2192  0.038 0.625
PT 0.1061  0.0349 0.000 0.096  0.0086 0.000
CFZ 0.1033  0.0091 0.000 0.1091  0.0173 0.000
AM 0.1136  0.0147 0.000 0.1142  0.0122 0.000
CPM 0.1023  0.0095 0.000 0.1019  0.0137 0.000
LZD + LFX 0.0924  0.011 0.000 0.0885  0.0055 0.000
LZD + PAS 0.1062  0.0187 0.000 0.1014  0.0096 0.000
LZD + PT 0.093  0.0059 0.000 0.0808  0.0063 0.000
LZD + CFZ 0.1039  0.0112 0.000 0.091  0.0094 0.000
LZD + AM 0.0996  0.0139 0.000 0.0923  0.0028 0.000
LZD + CPM 0.0975  0.0237 0.000 0.0953  0.0051 0.000
RHZc 0.1044  0.0056 0.000 0.0851  0.0076 0.000
LZD, linezolid; LFX, levoﬂoxacin; PAS, para-aminosalicylic acid; PT, prothionamide; CFZ, clofazimine; AM, amikacin; CPM, capreomycin.
a For the comparison with the spleen weight of the control group, respectively.
c Rifampicin + isoniazid + pyrazinamide.
Table 4
Bacterial colony-forming unit (CFU) counts in the lungs of mice after 1 month (M1) and 2 months (M2) of treatment
Treatment groups Day 14 Day 0 Bacterial count in lung (log10 CFU/organ)
M1 p-Valuea M2 p-Valuea
3.53  0.07 5.24  0.55
Control 7.9  0.49 7.76  0.16
LZD 6.15  0.13 0.000 5.68  0.22 0.000
LFX 7.33  0.19 0.006 7.07  0.45 0.000
PAS 7.52  0.2 0.125 7.5  0.10 0.319
PT 5.51  0.33 0.000 5.2  0.14 0.000
CFZ 5.85  0.11 0.000 4.61  0.26 0.000
AM 6.03  0.15 0.000 5.57  0.21 0.000
CPM 5.72  0.21 0.000 5.40  0.18 0.000
LZD + LFX 6.34  0.30 0.000 5.28  0.08 0.000
LZD + PAS 6.2  0.21 0.000 5.59  0.29 0.000
LZD + PT 6.18  0.20 0.000 5.23  0.07 0.000
LZD + CFZ 5.61  0.17 0.000 4.32  0.09b,c 0.000
LZD + AM 5.85  0.26 0.000 4.96  0.19 0.000
LZD + CPM 5.58  0.24 0.000 4.21  0.15b,c 0.000
RHZd 4.52  0.33 0.000 3.24  0.14 0.000
LZD, linezolid; LFX, levoﬂoxacin; PAS, para-aminosalicylic acid; PT, prothionamide; CFZ, clofazimine; AM, amikacin; CPM, capreomycin.
a For the comparison with the bacterial count in the control group, respectively.
b p < 0.05, for the comparison of the CFU of these two groups treated at 2 months with that at day 0.
c p < 0.05, for the comparison of the CFU of these two groups treated at 2 months with that of LZD alone.
d Rifampicin + isoniazid + pyrazinamide.
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of therapy; however, the reduction in spleen weight with LZD +
PAS was not greater than that with LZD alone.
3.4. Enumeration of CFU in the lungs
On the day after aerosol infection (day 14), the mean CFU
count was 3.53  0.07 log10 in the lungs. The lung CFU count at the
initiation of treatment (day 0), 15 days after infection, was
5.24  0.55 log10. The results of culture of the organs are summarized
in Table 4.
After 1 month of treatment, the CFUs of each treatment group
(except PAS, p = 0.125) were signiﬁcantly decreased (p < 0.05) by
1.56–2.39 log10 when compared with the control group. After
2 months of treatment, the CFUs of each treatment group (except
PAS, p = 0.319) dropped even further (p < 0.05) by 2.08–3.55 log10.
When comparing the activity of the combination treatments
with LZD alone against H37Rv, with the exception of LZD + CFZ and
LZD + CPM (p < 0.05), none of the combination treatments reduced
CFU more than LZD alone after either 1 or 2 months. In addition,although the combination of LZD + CFZ was more active in reducing
CFU than LZD alone, this combination was not superior to CFZ
alone (p > 0.05). Unlike LZD + CFZ, LZD + CPM displayed more
bactericidal activity than both LZD and CPM alone (p < 0.05).
Among all of the treatment groups, LZD + CPM had the greatest
activity against H37Rv, reducing CFU by 3.55 log10 after 2 months
of treatment, while LZD + CFZ reduced CFU by 3.44 log10. However,
none of the combinations was more active than the standard
regimen RIF + INH + PZA (Figure 1).
4. Discussion
It has been demonstrated clearly that treatment regimens
against TB should be made up of three or four anti-TB agents. In
reference to MDR-TB and XDR-TB, four or ﬁve anti-TB agents
should be included in the treatment regimen to overcome the
resistance of M. tuberculosis.15 High synergistic interactions have
been reported to reduce the toxicity or increase the therapeutic
efﬁcacy of regimens to some extent.16 Therefore, evaluating the
Figure 1. Efﬁcacy of regimens against H37Rv in mice during treatment (1 month and 2 months after treatment)
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physicians to design the most appropriate regimen.
Based on the in vitro results from the current study, indifference
or an additive effect was observed for most of the combinations,
with the exception of LZD + CPM, which displayed partial
synergism (FIC = 0.75) for three of four isolates. Because different
deﬁnitions are used to determine the interaction patterns of drugs,
it is necessary to discuss the criteria used to deﬁne the interaction
patterns. One deﬁnition of interaction widely used in the ﬁeld of
antimicrobial drug combinations is the following: synergistic
interactions, FIC < 0.5; no interaction, FIC >0.5, but <4; antago-
nistic activity, FIC>4.0.12 Using this deﬁnition to evaluate the
interaction patterns of LZD and second-line drugs, all combinations
studied would be ‘no interaction’. However, comparing this
conclusion with the interpretation of the present results, there
is no contradiction. The only difference is that ‘no interaction’ (FIC
>0.5–4) was further divided into three parts: partial synergy (FIC
>0.5–1), additive (FIC = 1), and indifference (FIC >1, but <4); this is
also often used in the ﬁeld of drug combination studies.
In anti-TB clinics, there is no one regimen against MDR-TB that
is accepted by all physicians. When doctors design regimens
against MDR-TB, they always take into account the situation
regarding resistance, as well as the MIC of drugs, due to the limited
choice of effective drug combinations. Although no synergy was
found between LZD and second-line anti-TB agents (FIC >0.5) in
the present study, the MIC of CPM decreased four times and that
of LZD decreased two times when combined with each other.
The extent of this decrease is the most prominent among all the
combinations studied. With the current data interpretation, the
ﬁnding of the partial synergy effect with the combination of LZD
and CPM for TB treatment should be highlighted. It is believed that
this could provide physicians with a potentially better choice of
drug combination and, therefore, beneﬁt TB patients.
Owing to the lack of correlation between the activities of the
antibiotic combinations in vitro and in vivo, an animal experimen-
tal model will be required to conﬁrm the results observed in vitro.
Because AM and KM belong to the aminoglycoside group of
antibiotics and MFX and LFX belong to the quinolone group of
antibiotics, AM and LFX were selected as the representatives of the
aminoglycoside and the quinolone group of antibiotics, respec-
tively, in the evaluation of the activity of combinations in vivo.
Another reason they were selected is that AM and LFX are
frequently the ﬁrst choice for the treatment of MDR-TB in the
clinic.
Based on the results from the in vivo experiments, no
antagonistic activity was observed between LZD and anysecond-line anti-TB agents; this was veriﬁed by the indicators of
spleen weight and CFU in the lungs. These results are consistent
with those of Rey-Jurado et al., who observed indifferent
interactions between LZD and AM and between LZD and LFX.17
After 2 months of treatment, none of these combinations
completely eradicated M. tuberculosis in the lungs. Therefore, a
regimen against MDR-TB including LZD should also include
additional second-line drugs.
There appears to be no single reasonable method to interpret
the in vivo experimental results of antimicrobial interactions. Had
the results of antimicrobial interactions been interpreted using the
time–kill methodology based on the discussion by Eliopoulos and
Moellering13 (in which synergy was deﬁned as a 2 log10 decrease
in viable count at 24 h with the combination, compared with the
most active single drug; indifference was deﬁned as a <1 log10
decrease in viable count at 24 h with the combination, compared
with the most active single antimicrobial alone; antagonism was
deﬁned as a 2 log10 increase in colony count at 24 h with the
combination, compared with the most active single drug alone),
the likely conclusion would have been that the combination of LZD
and CPM exhibited partial synergy against H37Rv because more
than a 1 log10 decrease in viable count in the LZD + CPM group at
2 months compared with the most active single drug, CPM, was
observed (Figure 1). This is consistent with the in vitro results.
Although the FIC of LZD + PAS was also 0.75 against H37Rv, the
combination of LZD + PAS did not show partial synergy in vivo
probably because of the poor penetration of PAS in the mouse
cell.18
Although LZD is increasingly used to treat MDR-TB, the severe
adverse reactions of this drug limit its use in MDR-TB patients.
Fortunately, a meta-analysis showed that a dose reduction resulted
in a lower frequency of both adverse events and adverse events
necessitating discontinuation of treatment with LZD.8 Among the
published data, the lowest rate of adverse effects was observed in
patients administered a dose of 300 mg LZD once daily.19 These
data indicate that a dose reduction may be particularly helpful in
reducing the adverse effects of LZD. Therefore, how to decrease the
dose of LZD in regimens and maintain its effect at the same time is
vitally important. With regard to the pharmacokinetic/pharmaco-
dynamic properties of LZD, the area under the curve (AUC0–24 h)/
MIC values are often used to evaluate the activity of LZD against M.
tuberculosis.20 In the present study, the addition of sub-MICs of
CPM or CFZ resulted in a two-fold reduction in the MIC of LZD,
meaning the same AUC0–24 h/MIC values could be achieved even if
LZD was given at a lower dose. Thus, to treat MDR-TB, the dose of
LZD may be reduced by combining CPM or CFZ. In addition, it is
W. Zhao et al. / International Journal of Infectious Diseases 52 (2016) 23–2828known that a portion of the bacterial population in patients with
active disease persists in a non-replicating state and CPM has been
reported to exhibit a clear bactericidal effect against non-
replicating M. tuberculosis in anaerobic conditions in vitro.21
Therefore, LZD + CPM is likely a potentially active combination that
could be included in regimens against MDR-TB.
In conclusion, this study demonstrated that no antagonistic
activity was found between LZD and second-line anti-TB drugs.
Among the combinations, LZD + CPM displayed the most activity
against H37Rv in vivo and showed partial synergism only. LZD
alone or in combination with one other second-line anti-TB drug
was not sufﬁcient to eradicate M. tuberculosis and more agents
should be included to form an effective regimen.
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